Skip to content
naulon
Not checkedNot checked for notices yet.

Susceptibility of important Gram-negative pathogens to tigecycline and other antibiotics in Latin America between 2004 and 2010

Fernández-Canigia Liliana, Dowzicky Michael J

Annals of Clinical Microbiology and Antimicrobials · 2012

doi:10.1186/1476-0711-11-29 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

<p>Abstract</p> <p>Background</p> <p>The Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) is a global surveillance study of antimicrobial susceptibility. This study reports data from Gram-negative isolates collected from centers in Latin America between 2004 and 2010.</p> <p>Methods</p> <p>Consecutive bacterial isolates were tested at each center using broth microdilution methodology as described by the Clinical Laboratory Standards Institute (CLSI). Susceptibility was determined using the CLSI interpretive criteria. For tigecycline the US Federal Drug Administration (FDA) criteria were used.</p> <p>Results</p> <p>A total of 16 232 isolates were analyzed. Susceptibility to imipenem, meropenem, and tigecycline was >95% against both non-extended-spectrum β-lactamase (ESBL) and ESBL producing <it>Escherichia coli</it>. Susceptibility to amikacin was also >95% for non-ESBL <it>E. coli</it>. 24.3% of <it>E. coli</it> were ESBL producers, ranging from 11.2% (58/519) in Colombia to 40.3% (31/77) in Honduras. Greater than 90% of non-ESBL <it>Klebsiella pneumoniae</it> were susceptible to tigecycline, carbapenems and amikacin. 35.3% of <it>K. pneumoniae</it> were ESBL producers, ranging from 17.2% (36/209) in Venezuela to 73.3% (55/75) in Honduras, with only imipenem and tigecycline maintaining >90% susceptibility. Greater than 90% of <it>Klebsiella oxytoca</it>, <it>Enterobacter</it> spp., and <it>Serratia marcescens</it> were susceptible to amikacin, carbapenems and tigecycline. The highest rates of susceptibility against <it>Acinetobacter baumannii</it> were seen for minocycline (89.4%) and imipenem (62.5%), while 95.8% of the <it>A. baumannii</it> isolates displayed an MIC ≤2 μg/mL for tigecycline.</p> <p>Conclusions</p> <p>In this study carbapenems and tigecycline remain active against Enterobacteriaceae and <it>A. baumannii</it>; however, there is cause for concern with carbapenem non-susceptible isolates reported in all countries included in this study.</p>

Abstract licence: CC BY-NC-ND

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.